絞り込み

16535

広告

Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.

著者 Miller K , Steger GG , Niepel D , Lüftner D この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (32view , 0users)

Full Text Sources

Patients with prostate cancer are at risk of impaired bone health. Prostate cancer has a propensity to metastasize to bone, after which patients are at risk of skeletal-related events (SREs). These complications are associated with increased mortality, substantial pain, and reduced quality of life. Patients are also at risk of bone loss due to androgen deprivation therapy (ADT), which can be compounded in elderly patients with reduced bone density. It is essential, therefore, that aspects of bone health and therapies able to prevent the occurrence of SREs are considered throughout the clinical course of prostate cancer.
PMID: 29988100 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード